Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;16(19):1635-1640.
doi: 10.2217/nnm-2021-0097. Epub 2021 Jun 25.

2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology

Martin Panigaj  1 , Marina A Dobrovolskaia  2 , Kirill A Afonin  3
Affiliations
Editorial

2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology

Martin Panigaj et al. Nanomedicine (Lond). 2021 Aug.
No abstract available

Keywords: drug delivery; immunotherapy; mRNA vaccines; nucleic acid nanoparticles; therapeutic nucleic acids.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Numbers R01GM120487 and R35GM139587 (to KA Afonin). The study was funded in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract 75N91019D00024 (to MA Dobrovolskaia). M Panigaj's involvement in this publication is the result of the project implementation: open scientific community for modern interdisciplinary research in medicine (OPENMED), ITMS2014+: 313011V455 supported by the Operational Program Integrated Infrastructure, funded by the European Regional Development Fund (ERDF). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Afonin KA, Dobrovolskaia MA, Church G, Bathe M. Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology. ACS Nano 14(8), 9221–9227 (2020). - PMC - PubMed
    1. Weng Y, Huang Q, Li C et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol. Ther. Nucleic Acids 19, 581–601 (2020). - PMC - PubMed
    1. Laczko D, Hogan MJ, Toulmin SA et al. A Single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53(4), 724–732 e727 (2020). - PMC - PubMed
    1. Corbett KS, Edwards DK, Leist SR et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830), 567–571 (2020). - PMC - PubMed
    1. Sahin U, Muik A, Derhovanessian E et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 586(7830), 594–599 (2020). - PubMed

Publication types